Michael Q.
- Country
- Germany
- Department
- Medizinische Klinik II
Research Overview
- Safety Study of Ivosidenib in Patients with Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
- Evaluation of Gemcitabine, Cisplatin, Trastuzumab, and Pembrolizumab in HER2-Positive Biliary Tract Cancer: A Phase II Clinical Trial
- Evaluation of Sacituzumab Govitecan in Metastatic Esophagogastric Adenocarcinoma: A Phase Ib/II Single-Arm Multicenter Study
Data & Insights
Has run more than one trial at 135 of 315 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating gastric cancer and esophagogastric junction adenocarcinoma, with particular focus on advanced and metastatic disease states. Their research extends to innovative therapeutic approaches for colorectal cancer, especially in metastatic settings.
- Gastric and Esophagogastric Cancer Management
- Colorectal Cancer Treatment Strategies
- Advanced Disease Interventions
Hepatobiliary Oncology
Demonstrates significant expertise in treating biliary tract cancers and cholangiocarcinoma. The investigator's work encompasses both locally advanced and metastatic disease states, with particular attention to gallbladder carcinoma treatment approaches.
- Biliary Tract Cancer Therapeutics
- Advanced Cholangiocarcinoma Treatment
- Post-Resection Care Strategies
Pancreatic and Neuroendocrine Tumors
Focuses on treating pancreatic ductal adenocarcinoma and neuroendocrine neoplasia. The investigator's expertise includes both surgical aftercare and advanced disease management, with particular emphasis on low proliferative neuroendocrine tumors.
- Pancreatic Cancer Treatment
- Neuroendocrine Tumor Management
- Post-Surgical Therapeutic Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.